

NEUROENDOCRINE CANCER UK

England & Wales · Charity number 1092386

Details

Other names LIVING WITH CARCINOID, NET PATIENT FOUNDATION, NET PATIENT FOUNDATION INCORPORATING LIVING WITH CARCINOID, NEUROENDOCRINE CANCER UK

Status Registered

Legal form Other

Registered 2002-06-11

Register [View on the Charity Commission register](#)

Contact

Address 74 Upper Holly Walk
Leamington Spa
Warwickshire
CV32 4JL

Phone 01926883487

Email catherine@nc-uk.org

Website www.neuroendocrinecancer.org.uk

Activities

Objects: 1. TO ADVANCE THE EDUCATION OF THE GENERAL PUBLIC (INCLUDING RELEVANT MEDICAL AND SCIENTIFIC COMMUNITIES) IN ALL AREAS RELATING TO NETS. 2. TO PROMOTE THE PHYSICAL AND MENTAL HEALTH OF THOSE AFFECTED BY NETS THROUGH THE PROVISION OF SUPPORT, ADVICE AND EDUCATION TO PATIENTS, THEIR CARERS AND FAMILY MEMBERS

Activities: 1. To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs. 2. To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, carers and family members.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-09-30	£695,569	£567,254	£1,117,726	10
2024-09-30	£720,464	£481,258	£989,421	10
2023-09-30	£492,208	£430,768	-	-
2022-09-30	£398,765	£387,521	-	-
2021-09-30	£575,569	£361,031	£677,532	6

Trustees

Name	Role	Appointed
PETER HOWARD GWILLIAM	Chair	
DAVID JOHN AMES		2024-03-05
Dr GORDON BROWN		2024-03-25
Dr Rajaventhana Srirajaskanthan		2014-01-20
Emma Brown		2023-01-20
JOHN MICHAEL KENT		2021-12-01
Tom Peter Jackson		2021-06-07

NEUROENDOCRINE CANCER UK

England & Wales - Charity number 1092386

Accounts

**NEUROENDOCRINE CANCER UK
TRUSTEES' REPORT AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025**



Chapman Worth
Chartered Accountants

Chapman Worth Limited

Neuroendocrine Cancer UK Contents

	Page
Trustees' Report	1—6
Independent Examiner's Report	7
Statement of Financial Activities	8
Comparative Statement of Financial Activities	9
Statement of Financial Position	10
Notes to the Financial Statements	11—16
The following pages do not form part of the statutory accounts:	
Detailed Statement of Financial Activities	17—18

Neuroendocrine Cancer UK Trustees' Report For The Year Ended 30 September 2025

The trustees present their report and the financial statements for the year ended 30 September 2025.

Objectives and Activities

Aims and Objectives

The constitutional Objectives of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK (ii) excellence in support, care, treatment, and research (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

Public Benefit

Neuroendocrine Cancer UK (NCUK) exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are not uncommon.

We work hard as an evidence-based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and self-confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, and sadness. For neuroendocrine cancer patients, specifically, the prospect of a cure is often nil, and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis, they can often be treated for the wrong disease, meaning their cancer pathway begins with feelings of extreme frustration. After treatment patients must address the gravity of their diagnosis at home, and often without regular access to the support of experts. Therefore, patients frequently suffer from feelings of abandonment, and struggle to know in whom to confide. Indeed, if their cancer is particularly advanced, they will face the possibility of dying. From our experience, the complexity of neuroendocrine cancer means that friends and family often struggle to comprehend their suffering.

...CONTINUED

**Neuroendocrine Cancer UK
Trustees' Report (continued)
For The Year Ended 30 September 2025**

Public Benefit - continued

People with a less common cancer, like neuroendocrine cancer, are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experience and to take positive and meaningful steps to address them.

The trustees confirm that they have complied with the requirements of Section 17 of the Charities Act 2011 to have due regard to the Charity Commission's guidance on public benefit.

Achievements and Performance

Main Achievements

Chief Executive's Report October 2024-September 2025

Strengthening our foundations

The period from October 2024 to September 2025 has been one of significant progress and consolidation for Neuroendocrine Cancer UK (NCUK). Throughout the year, we focused on strengthening our foundations while continuing to grow our reach, influence and impact for those affected by neuroendocrine cancer.

We made a strong start on integrating and cleansing our database, an important step that will enable us to use data more effectively as we look ahead. This work supports informed decision-making, strengthens governance, and underpins the delivery of our five-year strategy, launched during the year to guide the next phase of our development.

Expanding patient support and education

We continued to expand and diversify our support and education offer for patients and families. Alongside our patient support groups, counselling services and helpline, we launched a programme of monthly webinars featuring expert speakers. These webinars further empower our community by providing trusted, accessible information to support learning and understanding for patients and their families.

Improving awareness among healthcare professionals

We developed our Spotlight on Neuroendocrine Cancer campaign, aimed at healthcare professionals who are not specialists in neuroendocrine cancer, but who will nonetheless encounter and treat these patients. The campaign focuses on improving awareness of the unique needs of this patient group, providing practical support, and encouraging timely referral into specialist care. This year saw the launch of neuroendocrine cancer patient case studies to support healthcare professionals recognise the disease.

Supporting mental health and wellbeing

As part of the Spotlight on Neuroendocrine Cancer campaign, and in collaboration with Rare Minds, we developed Conversation Openers, an initiative arising from our Open Conversations report on neuroendocrine cancer and mental health. These 'bitesize' videos equip healthcare professionals with practical communication strategies to support sensitive conversations around mental health and wellbeing. This work reflects our ongoing commitment to addressing the psychosocial as well as the physical impact of neuroendocrine cancer.

...CONTINUED

**Neuroendocrine Cancer UK
Trustees' Report (continued)
For The Year Ended 30 September 2025**

Main Achievements - continued

Advancing Research

Advancing Research is our campaign dedicated to improving understanding of neuroendocrine cancer through targeted research that makes a real difference for patients and families. This year, we funded a proof-of-concept research project totalling £50,000, supporting innovative work that could shape future care.

We also entered the second year of our three-year research partnership with the Royal College of Surgeons, contributing £10,000 to fund the first Surgical Specialty Lead (SSL) in neuroendocrine cancer. With only 22 SSLs in the UK, this appointment represents a unique opportunity to drive research, raise awareness, and build expertise within the wider surgical community, ultimately improving care for patients.

In addition, we were delighted to launch a James Lind Alliance (JLA) Priority Setting Partnership (PSP) in neuroendocrine cancer. This important national initiative brings together patients, carers, and healthcare professionals to identify and prioritise the most pressing unanswered questions in diagnosis, treatment, and care. By ensuring research reflects the real experiences and needs of those affected, the PSP is helping shape a more patient-centred and impactful research agenda.

Recognising Our Community: NCUK Hero Awards

This year, we were proud to launch our Hero Awards, a new initiative designed to recognise the outstanding contributions of individuals within the neuroendocrine cancer community. The awards were created to celebrate the bravery & resilience of those with neuroendocrine cancer, the support and dedication from the medical professionals and the love and support given by their friends & family.

The launch of the Hero Awards generated strong engagement across our community, with nominations and positive feedback reflecting the value placed on recognition and shared experience. The initiative not only highlighted individual achievements but also strengthened community connection, reinforcing the importance of visibility, appreciation and peer support within a condition that is often overlooked.

Community Engagement

This year, our marketing activity was strengthened through the launch of Loop, our new monthly newsletter, designed to engage our audience and highlight our support services, education programmes, campaigns and opportunities to get involved. We significantly increased our social media presence which continues to play a vital role in raising awareness of neuroendocrine cancer and keeping our community informed and connected.

Fundraising and Community Engagement

To strengthen community-led fundraising, we appointed a Community Fundraiser to support, encourage and work alongside individuals and groups raising funds for NCUK. We also supported one of our partners Daily Dip 4 Dave which saw supporters across the UK take part in cold water swimming challenges to raise vital funds for neuroendocrine cancer research.

Collaboration

Collaboration has been a key theme throughout the year, particularly in relation to improving the collation of critical data and enhancing understanding of neuroendocrine cancers. Our work has involved close collaboration with NHS partners, the National Cancer Research Institution (NCRI), the National Cancer Registration and Analysis Service (NCRAS), ENETS Centres of Excellence, expert neuroendocrine multidisciplinary teams, medical and nursing societies, advocacy organisations including Cancer 52 and the International Neuroendocrine Cancer Alliance (INCA), political and policy bodies in the UK and internationally, and engagement with the pharmaceutical industry.

...CONTINUED

**Neuroendocrine Cancer UK
Trustees' Report (continued)
For The Year Ended 30 September 2025**

Main Achievements - continued

None of this work would be possible without the dedication of our staff, trustees, volunteers, partners and supporters. As we look ahead, we do so with confidence, gratitude and a shared commitment to improving outcomes for those affected by neuroendocrine cancer.

Financial Review

Financial Position

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £128,305 (2024 £239,206) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £1,117,726 (2024 £989,421) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies.

Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs

Reference and Administrative Details

Trustees

Mr P Gwilliam - Chairman
Dr G Brown
Mr D Ames
Ms E Brown
Mr J Kent
Mr T Jackson
Dr R Srirajaskanthan

Charity Number

1092386

Principal Address

Second Floor, Holly House
74 Upper Holly Walk
Leamington Spa
Warwickshire
CV32 4JL

Independent Examiner

Anna Chapman FCA
Chapman Worth Limited

**Neuroendocrine Cancer UK
Trustees' Report (continued)
For The Year Ended 30 September 2025**

Chartered Accountants
2 The Old Estate Yard
East Hendred
Wantage
Oxfordshire
OX12 8JY

**Neuroendocrine Cancer UK
Trustees' Report (continued)
For The Year Ended 30 September 2025**

The trustees' report was approved by the board of trustees and signed on its behalf by:



Mr P Gwilliam

Trustee

Date

6th February 2026.

Neuroendocrine Cancer UK
Independent Examiner's Report to the Trustees of Neuroendocrine Cancer UK
For The Year Ended 30 September 2025

I report to the trustees on my examination of the accounts of Neuroendocrine Cancer UK (the Trust) for the year ended 30 September 2025.

Responsibilities and Basis of Report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.


Independent Examiner's Statement

Since the Trust's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and contents of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Anna Chapman FCA

Date
Chapman Worth Limited
Chartered Accountants
2 The Old Estate Yard
East Hendred
Wantage
Oxfordshire
OX12 8JY

4 March 2026

Neuroendocrine Cancer UK
Statement of Financial Activities
For The Year Ended 30 September 2025

		Unrestricted funds	Restricted funds	2025 Total funds	2024 Total funds
	Notes	£	£	£	£
INCOME AND ENDOWMENTS FROM:					
Donations and legacies	3	594,698	92,525	687,223	709,841
Other trading activities	4	2,744	-	2,744	4,107
Investments	5	5,592	-	5,592	6,516
		<u>603,034</u>	<u>92,525</u>	<u>695,559</u>	<u>720,464</u>
EXPENDITURE ON:					
Raising funds	6	(989)	-	(989)	(7,357)
Charitable activities:	6				
Charitable activities		(485,581)	(80,684)	(566,265)	(473,901)
		<u>(486,570)</u>	<u>(80,684)</u>	<u>(567,254)</u>	<u>(481,258)</u>
NET INCOME		116,464	11,841	128,305	239,206
Transfers between funds	14	10,797	(10,797)	-	-
NET MOVEMENT IN FUNDS		127,261	1,044	128,305	239,206
RECONCILIATION OF FUNDS:					
Total funds brought forward		953,050	36,371	989,421	750,215
TOTAL FUNDS CARRIED FORWARD	14	<u><u>1,080,311</u></u>	<u><u>37,415</u></u>	<u><u>1,117,726</u></u>	<u><u>989,421</u></u>

The notes on pages 11 to 16 form part of these financial statements.

Neuroendocrine Cancer UK
Comparative Statement of Financial Activities
For The Year Ended 30 September 2025


		Unrestricted funds	Restricted funds	2024 Total funds
	Notes	£	£	£
INCOME AND ENDOWMENTS FROM:				
Donations and legacies	3	604,451	105,390	709,841
Other trading activities	4	4,107	-	4,107
Investments	5	6,516	-	6,516
		<u>615,074</u>	<u>105,390</u>	<u>720,464</u>
EXPENDITURE ON:				
Raising funds	6	(7,357)	-	(7,357)
Charitable activities:	6			
Charitable activities		(395,938)	(77,963)	(473,901)
		<u>(403,295)</u>	<u>(77,963)</u>	<u>(481,258)</u>
NET INCOME		<u>211,779</u>	<u>27,427</u>	<u>239,206</u>
NET MOVEMENT IN FUNDS		<u>211,779</u>	<u>27,427</u>	<u>239,206</u>
RECONCILIATION OF FUNDS:				
Total funds brought forward		741,271	8,944	750,215
TOTAL FUNDS CARRIED FORWARD	14	<u><u>953,050</u></u>	<u><u>36,371</u></u>	<u><u>989,421</u></u>

The notes on pages 11 to 16 form part of these financial statements.

**Neuroendocrine Cancer UK
Statement of Financial Position
As At 30 September 2025**

	Notes	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
CURRENT ASSETS					
Debtors	11	4,207	-	4,207	3,084
Cash at bank and in hand		1,091,040	37,415	1,128,455	996,026
		<u>1,095,247</u>	<u>37,415</u>	<u>1,132,662</u>	<u>999,110</u>
Creditors: Amounts Falling Due Within One Year	12	(14,936)	-	(14,936)	(9,689)
		<u>1,080,311</u>	<u>37,415</u>	<u>1,117,726</u>	<u>989,421</u>
NET CURRENT ASSETS (LIABILITIES)					
		<u>1,080,311</u>	<u>37,415</u>	<u>1,117,726</u>	<u>989,421</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>1,080,311</u>	<u>37,415</u>	<u>1,117,726</u>	<u>989,421</u>
NET ASSETS					
		<u>1,080,311</u>	<u>37,415</u>	<u>1,117,726</u>	<u>989,421</u>
FUNDS OF THE CHARITY					
Restricted Funds				37,415	36,371
Unrestricted Funds				1,080,311	953,050
TOTAL FUNDS	14			<u>1,117,726</u>	<u>989,421</u>

On behalf of the board



Mr P Gwilliam

Trustee

Date

6th February 2026

The notes on pages 11 to 16 form part of these financial statements.

Neuroendocrine Cancer UK
Notes to the Financial Statements
For The Year Ended 30 September 2025

1. General Information

Neuroendocrine Cancer UK is an unincorporated charity registered with the Charity Commission, registered charity number 1092386. The principal address is Second Floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)", Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities Act 2011.

The charity is a Public Benefit Entity as defined by FRS 102.

2.2. Incoming Resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

2.3. Resources Expended

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

Neuroendocrine Cancer UK
Notes to the Financial Statements (continued)
For The Year Ended 30 September 2025

2.4. Cash and Cash Equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.

3. Income from Donations and Legacies

			2025
	Unrestricted funds	Restricted funds	Total funds
	£	£	£
Donations and gifts	491,087	92,525	583,612
Legacies	103,611	-	103,611
	<u>594,698</u>	<u>92,525</u>	<u>687,223</u>
			2024
	Unrestricted funds	Restricted funds	Total funds
	£	£	£
Donations and gifts	456,502	105,390	561,892
Legacies	147,949	-	147,949
	<u>604,451</u>	<u>105,390</u>	<u>709,841</u>

4. Income from Other Trading Activities

	2025	2024
	Unrestricted funds	Unrestricted funds
	£	£
Income from other trading activities	<u>2,744</u>	<u>4,107</u>

5. Investment Income

	2025	2024
	Unrestricted funds	Unrestricted funds
	£	£
Bank interest receivable	<u>5,592</u>	<u>6,516</u>

Neuroendocrine Cancer UK
Notes to the Financial Statements (continued)
For The Year Ended 30 September 2025

6. Analysis of Expenditure

				2025
	Activities undertaken directly	Grant funding of activities	Support costs (see note 7)	Total
	£	£	£	£
Raising funds	989	-	-	989
Charitable activities	388,631	6,439	171,195	566,265
	<u>389,620</u>	<u>6,439</u>	<u>171,195</u>	<u>567,254</u>
				2024
	Activities undertaken directly	Grant funding of activities	Support costs (see note 7)	Total
	£	£	£	£
Raising funds	7,357	-	-	7,357
Charitable activities	346,051	7,639	120,211	473,901
	<u>353,408</u>	<u>7,639</u>	<u>120,211</u>	<u>481,258</u>

7. Support Costs

	2025
	Charitable activities
	£
Employee costs	119,592
Premises expenses	8,867
General administration	35,390
Interest payable	4,339
Governance costs	3,007
	<u>171,195</u>

Neuroendocrine Cancer UK
Notes to the Financial Statements (continued)
For The Year Ended 30 September 2025

	2024 Charitable activities £
Employee costs	96,639
Premises expenses	12,143
General administration	7,542
Governance costs	3,887
	120,211

Support cost allocation for the period.

Office Expenses 27% of the cost (2024 13%)
 Legal & Professional 53% of the cost (2024 43%)
 Computer running costs 9% of the cost (2024 9%)
 Rent & Rates 100% of the cost (2024 100%)
 Telecommunications 4% of the cost (2024 5%)
 Other costs 92% of the cost (2024 67%)

8. Independent Examiner's Remuneration

	2025 £	2024 £
Independent examination of the financial statements	1,975	3,887

9. Staff Costs

Staff costs were as follows:

	2025 £	2024 £
Wages and salaries	318,291	264,098

The number of employees whose employee benefits (excluding employer pension costs) for the reporting period exceeded £60,000 was:

	2025	2024
£60,000 to £69,999	1	1

10. Average Number of Employees

Average number of employees during the year was: 10 (2024: 11)

Neuroendocrine Cancer UK
Notes to the Financial Statements (continued)
For The Year Ended 30 September 2025

11. Debtors

	2025	2024
	£	£
Due within one year		
Other debtors	4,207	3,084
	4,207	3,084

12. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	-	182
Other creditors	4,765	2,481
Taxation and social security	7,981	4,938
Accruals and deferred income	2,190	2,088
	14,936	9,689

13. Pension Commitments

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund.

During the year the charge to the statement of financial activities in respect of defined contribution schemes was £6,019.

At the statement of financial position date contributions of £1,244 (2024: £939) were due to the fund and are included in creditors.

14. Movement in Funds

	As at 1 October 2024	Income	Expenditure	Transfers	As at 30 September 2025
	£	£	£	£	£
Unrestricted funds					
General:					
General unrestricted fund	953,050	603,034	(486,570)	10,797	1,080,311
Restricted funds					
Restricted fund	36,371	92,525	(80,684)	(10,797)	37,415
	989,421	695,559	(567,254)	-	1,117,726

Neuroendocrine Cancer UK
Notes to the Financial Statements (continued)
For The Year Ended 30 September 2025

	As at 1 October 2023	Income	Expenditure	As at 30 September 2024
	£	£	£	£
Unrestricted funds				
General:				
General unrestricted fund	741,271	615,074	(403,295)	953,050
Restricted funds				
Restricted fund	8,944	105,390	(77,963)	36,371
Total funds	<u>750,215</u>	<u>720,464</u>	<u>(481,258)</u>	<u>989,421</u>

15. Transactions with Trustees

No trustee expenses have been incurred.

16. Related Party Disclosures

There have been no related party transactions in the reporting period that require disclosure.

**Neuroendocrine Cancer UK
Detailed Statement of Financial Activities
For The Year Ended 30 September 2025**

	2025	2024
	Total funds	Total funds
	£	£
INCOME AND ENDOWMENTS FROM:		
Donations and legacies		
Donations and gifts	583,612	561,892
Legacies	103,611	147,949
	<u>687,223</u>	<u>709,841</u>
Other trading activities		
Income from other trading activities	2,744	4,107
	<u>2,744</u>	<u>4,107</u>
Investments		
Bank interest receivable	5,592	6,516
	<u>5,592</u>	<u>6,516</u>
	695,559	720,464
EXPENDITURE ON:		
Raising funds		
Cost of raising funds	(990)	(7,357)
Employees' salaries whose contracts are with and are paid by a related party	1	-
	<u>(989)</u>	<u>(7,357)</u>
Charitable Activities:		
Charitable activities		
Strategic activities	(154,403)	(152,050)
Professional costs	(6,414)	-
Staging fundraising events	(6,537)	-
Subcontractor costs	-	(7,069)
Wages and salaries	(198,700)	(167,459)
Travel and subsistence expenses	(8,598)	-
Computer software, IT consumables and maintenance	(1,133)	(1,563)
Marketing and advertising costs	(2,718)	(9,781)
Support and administration costs	-	(5,046)
Data and telecommunications costs	(2,704)	(2,422)
Printing, postage and stationery	(6,916)	-
Subscriptions	(508)	-
Other direct costs	-	(661)
Grants to institutions	-	(7,639)
Grants to individuals	(6,439)	-
Wages and salaries	(119,592)	(96,639)

...CONTINUED

Neuroendocrine Cancer UK
Detailed Statement of Financial Activities (continued)
For The Year Ended 30 September 2025

Rent	(8,867)	(12,143)
Computer software, consumables and maintenance	(18,074)	(1,401)
Telecommunications and data costs	(117)	(116)
Independent examiner's fees	(1,975)	-
Legal fees	(7,339)	(3,378)
Bookkeeping fees	(5,364)	-
Other office costs	(2,521)	(2,157)
Sundry expenses	-	(490)
Bank charges	(4,339)	-
AGM / board meetings expenses	(3,007)	-
Independent examiner's fees	-	(3,887)
	<u>(566,265)</u>	<u>(473,901)</u>
	<u>(567,254)</u>	<u>(481,258)</u>
NET INCOME	<u>128,305</u>	<u>239,206</u>

NEUROENDOCRINE CANCER UK

England & Wales - Charity number 1092386

Accounts

Charity registration number 1092386

NEUROENDOCRINE CANCER UK
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

NEUROENDOCRINE CANCER UK

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Dr R Srirajaskanthan Mr J Kent Mr T Jackson Mr P Gwilliam (Chairman) Mr D Bartlett Ms E Brown Mr D Ames Mr G Brown	(Appointed 23 March 2024) (Appointed 23 March 2024)
Charity number	1092386	
Principal address	Second Floor Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 4JL	
Independent examiner	Chapman Worth Limited 2 The Old Estate Yard High Street East Hendred Wantage Oxfordshire OX12 8JY	

NEUROENDOCRINE CANCER UK

CONTENTS

	Page
Trustees' report	1 - 6
Independent examiner's report	7
Statement of financial activities	8
Statement of financial position	9
Notes to the financial statements	10 - 18

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2024

The Trustees are pleased to present the Trustees' Report and Accounts of Neuroendocrine Cancer UK (NCUK) for the year ended 30 September 2023. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in Note 1 to the Accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The constitutional Objectives of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK (ii) excellence in support, care, treatment, and research (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Purpose and Need

Neuroendocrine Cancer UK (NCUK) exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are not uncommon.

We work hard as an evidence-based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and self-confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, and sadness. For neuroendocrine cancer patients, specifically, the prospect of a cure is often nil, and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis, they can often be treated for the wrong disease, meaning their cancer pathway begins with feelings of extreme frustration. After treatment patients must address the gravity of their diagnosis at home, and often without regular access to the support of experts. Therefore, patients frequently suffer from feelings of abandonment, and struggle to know in whom to confide. Indeed, if their cancer is particularly advanced, they will face the possibility of dying. From our experience, the complexity of neuroendocrine cancer means that friends and family often struggle to comprehend their suffering.

People with a less common cancer, like neuroendocrine cancer, are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experience and to take positive and meaningful steps to address them.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Achievements and performance

The CEO is supported by the Trustee board, a full-time and part-time specialist nurse, a part-time cancer support coordinator, 2 part-time administrative assistants, a full-time operations and digital lead, part-time campaigns lead and a part-time communications officer and community fundraising officer. NCUK's psychotherapy/ counselling service is contracted to the Rare Minds organisation, and we have freelance contractors supporting occasional projects, where we do not have the expertise or resource in house.

A dedicated group of patient ambassadors also support the work of the organisation. This group flexes in numbers due to personal health situations, but the work of this group is incredibly valuable to NCUK.

This financial year has been the final year of our current 3-year strategy and completing and delivering the key activities of this strategy has been our priority. These achievements include:

- The integration and cleansing of our database to support our need for data to drive and deliver our planned new 5-year strategy.
- The development and completion of our first of its kind interactive multimedia toolkit presented to our community in the form of a flipping book. This handbook provides a complete guide to living with neuroendocrine cancer and has over 7,000 views to date.
- The launch of our patient education services in the form of monthly webinars with invited expert speakers.
- The development of our Spotlight Campaign providing topline essential information to healthcare professionals not working in the neuroendocrine field but who will undoubtedly see and treat neuroendocrine cancer patients. Understanding the unique needs of this group, ensuring referral into expertise and understanding what can be done to expedite early treatments are all aims of this campaign.

In collaboration with Rare Minds, Neuroendocrine Cancer UK developed **Conversation Openers**, an initiative born from our Open Conversations report on neuroendocrine cancer and mental health. Launched in 2022, the report underscored the critical need for healthcare professionals to engage in open dialogues with neuroendocrine cancer patients and their families regarding mental health concerns. Recognising the unique psychosocial challenges faced by individuals with neuroendocrine cancer, Conversation Openers provides healthcare professionals with practical communication strategies to navigate discussions about mental health effectively. As part of our ongoing 'Spotlight on Neuroendocrine Cancer' campaign, these 'bitesize' videos offer insights into integrating mental health considerations into routine care and initiating sensitive conversations with patients.

- Funding of a proof-of-concept research project totalling over £50,000.
- Funding a partnership with the Royal College of Surgeons to develop research around surgical treatments for neuroendocrine cancer patients. This is a 3-year programme that we support with £10,000 per year.
- Collaborating on/driven various projects to improve the collation of important data, understanding and awareness about neuroendocrine cancers. Collaborations include:

1-NHS, the National Cancer Research Institution (NCRI) and the National Cancer Registration and Analysis Service (NCRAS)

2-ENETs Centres of Excellence and expert neuroendocrine multidisciplinary teams

3- Medical and nursing societies

4-Advocacy organisations such as Cancer 52 and the International Neuroendocrine Cancer Alliance (INCA)

5-Political/ Policy agencies both in the UK, Europe and Internationally

6-Pharmaceutical industry

- Increasing our social media presence considerably
- Launching the first of its kind Ideal Patient Pathway for neuroendocrine cancer patients. This project involved a wide stakeholder group of individuals across industry, the NHS and patients. This project also had a political arm as we took the pathway to Parliament looking to engage politicians with a health interest to support, share and talk about the need for a dedicated pathway for this patient group.
- Completing our national fundraiser for our Advancing Research Campaign. This campaign saw people across the UK cold water swimming for research.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Note from the CEO Cathy Bouvier Ellis

We support all those affected by neuroendocrine cancer through our support and information work, we influence infrastructure and optimal care through our advocacy and policy work, and we address public perceptions of neuroendocrine cancer through our education and awareness work.

We do this because although we have seen an increased knowledge and understanding with respect to classification, pathogenesis, treatment, and research regarding neuroendocrine cancers, and we have seen the growth of patient advocacy and real-world data about the lived experience of the patient community, we have also witnessed, heard and listened to the significant challenges a newly diagnosed patient has to contend with - a sense of being invisible, surrounded by the unfamiliar, especially terminology, diagnostics and treatments, not conforming to the 'treatment, recovery and survivorship/decline' model of cancer care, coping with uncertainty and ultimately having to live with cancer.

Data collection, interrogation, community surveys and polls have been undertaken this year to understand the needs of our community to support the development of our new 5-year strategy. This strategy development has been a focus of the last few months and focuses the organisation on 8 key strategic adaptations:

1. Simplification of who we are with a focus on the disease name
2. A less is more approach. Project plans justified with a clear strategic objective to improve the quality of life for neuroendocrine patients and families.
3. An increased investment in our marketing and generating income programmes.
4. More engagement with our community of patient's families and HCPs to drive the relevant projects over the next 5 years
5. Develop strong and realistic workplans with clear outputs and KPIs where possible.
6. Understanding our community through excellent data management and resourcing.
7. Implement new ways of working to create a positive culture in the organisation, a sense of worth and accountability.
8. Ensure staff empowerment and engagement is a focal point with the development of clear roles and job descriptions.

Looking forward to the next 5 years, these adaptations will allow us to drive forward with our strategic priorities:

- Empower and support more people affected by neuroendocrine cancer
- Educate a wider audience with reliable accurate and data driven information
- Effectively raise awareness of neuroendocrine cancer to a defined and relevant audience
- Invest in research, through funding of a balanced & broad research programme.

We were founded by patients, families & HCP's, therefore we must continue to listen and respond to the needs of our community as a primary objective; the voice of those affected directly by neuroendocrine cancer should remain at the heart of any decisions around our future.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £239,206 (2023 £61,440) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £989,421 (2023 £750,215) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies. Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs.

Structure, governance and management

Living with Carcinoid was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. The Constitution was amended on 9th February 2006 with the association's name changed to 'NET Patient Foundation incorporating Living with Carcinoid'. On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

Trustees

Dr R Srirajaskanthan

Mr J Kent

Mr T Jackson

Mr P Gwilliam (Chairman)

Mr D Bartlett

Ms E Brown

Mr D Ames

(Appointed 23 March 2024)

Mr G Brown

(Appointed 23 March 2024)

Recruitment and appointment of trustees

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

NEUROENDOCRINE CANCER UK

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 30 SEPTEMBER 2024

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The Trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All Trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The Trustees report was approved by the Board of Trustees.



Mr P Gwilliam (Chairman)

Trustee

Date: 14th JANUARY 2025

NEUROENDOCRINE CANCER UK

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2024.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Anna Chapman FCA
Chapman Worth Limited
2 The Old Estate Yard
High Street
East Hendred
Wantage
Oxfordshire
OX12 8JY

Dated:

15 January 2025

NEUROENDOCRINE CANCER UK

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 SEPTEMBER 2024

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Income from:							
Donations and legacies	3	604,451	105,390	709,841	472,828	14,195	487,023
Charitable activities	4	4,107	-	4,107	-	2,300	2,300
Investments	5	6,516	-	6,516	2,885	-	2,885
Total income		<u>615,074</u>	<u>105,390</u>	<u>720,464</u>	<u>475,713</u>	<u>16,495</u>	<u>492,208</u>
Expenditure on:							
Raising funds	6	7,357	-	7,357	2,637	-	2,637
Charitable activities	7	395,938	77,963	473,901	369,982	58,149	428,131
Total expenditure		<u>403,295</u>	<u>77,963</u>	<u>481,258</u>	<u>372,619</u>	<u>58,149</u>	<u>430,768</u>
Net income		211,779	27,427	239,206	103,094	(41,654)	61,440
Transfers between funds		-	-	-	(3,520)	3,520	-
Net movement in funds		211,779	27,427	239,206	99,574	(38,134)	61,440
Reconciliation of funds:							
Fund balances at 1 October 2023		<u>741,271</u>	<u>8,944</u>	<u>750,215</u>	<u>641,697</u>	<u>47,078</u>	<u>688,775</u>
Fund balances at 30 September 2024		<u>953,050</u>	<u>36,371</u>	<u>989,421</u>	<u>741,271</u>	<u>8,944</u>	<u>750,215</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.


NEUROENDOCRINE CANCER UK

STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2024

	Notes	2024 £	£	2023 £	£
Current assets					
Debtors	13	3,084		571	
Cash at bank and in hand		996,026		759,909	
		<u>999,110</u>		<u>760,480</u>	
Creditors: amounts falling due within one year	14	(9,689)		(10,265)	
Net current assets			<u>989,421</u>		<u>750,215</u>
The funds of the charity					
Restricted income funds	16		36,371		8,944
Unrestricted funds	17		953,050		741,271
			<u>989,421</u>		<u>750,215</u>

The financial statements were approved by the Trustees on 14th January 2025



Mr P Gwilliam (Chairman)
Trustee

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2024

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

1 Accounting policies

(Continued)

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

3 Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations and gifts	456,502	105,390	561,892	448,030	14,195	462,225
Legacies	147,949	-	147,949	24,798	-	24,798
	<u>604,451</u>	<u>105,390</u>	<u>709,841</u>	<u>472,828</u>	<u>14,195</u>	<u>487,023</u>

4 Income from charitable activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Charitable activities						
Other income	4,107	-	4,107	-	-	-
Grants						
Performance related grants	-	-	-	-	2,300	2,300
	<u>4,107</u>	<u>-</u>	<u>4,107</u>	<u>-</u>	<u>2,300</u>	<u>2,300</u>

5 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Interest receivable	<u>6,516</u>	<u>2,885</u>

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

6 Expenditure on raising funds

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Fundraising and publicity		
Other fundraising costs	7,357	2,637
	<u>7,357</u>	<u>2,637</u>

7 Expenditure on charitable activities

	Charitable activities 2024 £	Charitable activities 2023 £
Direct costs		
Staff costs	167,459	153,597
Staff costs	138,118	122,741
Strategic activities	13,932	11,084
Computer costs	1,563	4,774
Advertising & marketing	9,781	4,417
Telephone	2,422	2,850
Office expenses	5,046	8,187
Legal & Professional	7,069	3,800
Other costs	661	330
	<u>346,051</u>	<u>311,780</u>
Grant funding of activities (see note 9)	7,639	7,115
Share of support and governance costs (see note 10)		
Support	116,324	105,379
Governance	3,887	3,857
	<u>473,901</u>	<u>428,131</u>
Analysis by fund		
Unrestricted funds	395,938	369,982
Restricted funds	77,963	58,149
	<u>473,901</u>	<u>428,131</u>

8 Description of charitable activities

Charitable activities

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

9 Grants payable

	Charitable activities 2024 £	Charitable activities 2023 £
Grants to institutions:		
NCUK Virtual Toolkit	2,618	7,088
Welfare	5,021	-
NCUK Life Alliance	-	27
	<u>7,639</u>	<u>7,115</u>

10 Support costs allocated to activities

	2024 £	2023 £
	Basis of allocation	
Staff costs	<i>Administrative staff</i>	96,639
Office Expenses	<i>30% of the cost (2023 13%)</i>	86,137
Legal & Professional	<i>32% of the cost (2023 43%)</i>	2,157
Computer running costs	<i>9% of the cost (2023 13%)</i>	3,378
Rent & Rates	<i>100% of the cost (2023 100%)</i>	1,401
Telecommunications	<i>5% of the cost (2023 6%)</i>	12,143
Other costs	<i>43% of the cost (2023 67%)</i>	116
Governance costs	490	186
	3,887	685
	<u>120,211</u>	<u>109,236</u>
Analysed between:		
Charitable activities	<u>120,211</u>	<u>109,236</u>

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

11 Trustees

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year.

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

12 Employees

The average monthly number of employees during the year was:

2024 Number	2023 Number
12	9

Employment costs

	2024 £	2023 £
Wages and salaries	237,497	216,160
Social security costs	21,507	19,094
Other pension costs	5,094	4,480
	<u>264,098</u>	<u>239,734</u>

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2024 Number	2023 Number
> £60,000	1	1
£10,000 to £60,000	11	8

Remuneration of key management personnel

The remuneration of key management personnel was as follows:

	2024 £	2023 £
Aggregate compensation	<u>68,345</u>	<u>66,572</u>

13 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Other debtors	912	410
Prepayments and accrued income	2,172	161
	<u>3,084</u>	<u>571</u>

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2024

14 Creditors: amounts falling due within one year

	2024	2023
	£	£
Other taxation and social security	4,938	4,629
Trade creditors	182	1,007
Other creditors	2,481	2,643
Accruals and deferred income	2,088	1,986
	<u>9,689</u>	<u>10,265</u>

15 Retirement benefit schemes

	2024	2023
	£	£
Defined contribution schemes		
Charge to profit or loss in respect of defined contribution schemes	5,094	4,480
	<u>5,094</u>	<u>4,480</u>

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

16 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 October 2023	Incoming resources	Resources expended	Transfers	At 30 September 2024
	£	£	£	£	£
	8,944	105,390	(77,963)	-	36,371
	<u>8,944</u>	<u>105,390</u>	<u>(77,963)</u>	<u>-</u>	<u>36,371</u>
Previous year:					
	At 1 October 2022	Incoming resources	Resources expended	Transfers	At 30 September 2023
	£	£	£	£	£
	47,078	16,495	(58,149)	3,520	8,944
	<u>47,078</u>	<u>16,495</u>	<u>(58,149)</u>	<u>3,520</u>	<u>8,944</u>

NEUROENDOCRINE CANCER UK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2024

17 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 October 2023	Incoming resources	Resources expended	Transfers	At 30 September 2024
	£	£	£	£	£
General funds	741,271	615,074	(403,295)	-	953,050
	<u>741,271</u>	<u>615,074</u>	<u>(403,295)</u>	<u>-</u>	<u>953,050</u>
Previous year:	At 1 October 2022	Incoming resources	Resources expended	Transfers	At 30 September 2023
	£	£	£	£	£
General funds	641,697	475,713	(372,619)	(3,520)	741,271
	<u>641,697</u>	<u>475,713</u>	<u>(372,619)</u>	<u>(3,520)</u>	<u>741,271</u>

18 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
At 30 September 2024:			
Current assets/(liabilities)	953,050	36,371	989,421
	<u>953,050</u>	<u>36,371</u>	<u>989,421</u>
	<u>953,050</u>	<u>36,371</u>	<u>989,421</u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 30 September 2023:			
Current assets/(liabilities)	741,271	8,944	750,215
	<u>741,271</u>	<u>8,944</u>	<u>750,215</u>
	<u>741,271</u>	<u>8,944</u>	<u>750,215</u>

19 Related party transactions

There were no disclosable related party transactions during the year (2023 - none).

NEUROENDOCRINE CANCER UK

England & Wales - Charity number 1092386

Accounts

Charity registration number 1092386

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	Dr R Srirajaskanthan Mr J Kent Mr T Jackson Mr P Gwilliam (Chairman) Mr D Bartlett Ms E Brown	(Appointed 21 November 2022) (Appointed 20 January 2023)
Charity number	1092386	
Principal address	Second Floor Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 4JL	
Independent examiner	Chapman Worth Limited 2 The Old Estate Yard High Street East Hendred Wantage Oxfordshire OX12 8JY	
Bankers	Lloyds Bank Butler Place Branch PO Box 100 BX1 1LT	

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION CONTENTS

	Page
Trustees' report	1 - 5
Independent examiner's report	6
Statement of financial activities	7
Statement of financial position	8
Notes to the financial statements	9 - 19

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2023

The Trustees are pleased to present the Trustees' Report and Accounts of Neuroendocrine Cancer UK (NCUK) for the year ended 30 September 2023. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in Note 1 to the Accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives

The constitutional Objects of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK, (ii) excellence in support, care, treatment, and research, (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types, (iv) collaborative working and building an accessible approachable fraternity, and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

Purpose and Need

NCUK exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are common.

We work hard as an evidence-based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and self-confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support.

2023 was a pivotal year for the organisation as it celebrated its 21st year. At the end of 2022/23 we have 12,405 subscribers to our database, an increase of 451 in the year. We have seen increases of 16% in our e-bulletin subscribers and 41.5% in our website users, with a dramatic rise of 108% in our website views. For comparison, we have seen a 23% increase on our Facebook page followers, a 30% increase on our Instagram page followers and a 17% increase on our Twitter page followers.

Our core and most costly service is our support service. The review of the demands on this service in terms of our helpline highlighted a dramatic increase, with the highest recorded contact forms in Q3 2023 since 2019. Key drivers for this are the current state of the NHS, which has left the patient community with more need for accessible support, and NCUK's efforts to increase its database, social media output and reach.

"I thought I could cope with most things in life, but the recent 6-8 week wait for a plan of action and MDT has very nearly finished me mentally. If I had not called the Helpline for an extensive discussion and support, I don't know what would have happened. I had simply reached my limit of what I could cope with mentally, starting awake in the middle of the night with an adrenaline shot of fear. My wonderful discussion on the Helpline led to me attending my first Natter that very evening. I thoroughly enjoyed talking to others who actually understood how I had been feeling. Thank you to Kate and Nikie."

Helpline user.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Achievements and performance

The CEO is supported by the Trustee Board, a full-time (FT) and part-time (PT) specialist nurse, a cancer support coordinator (PT), 2 administrative assistants (PT), an operations and digital lead (FT), a campaigns lead (PT) and a communications officer (PT). NCUK's psychotherapy/counselling service is contracted to the Rareminds organisation, and we have freelance contractors supporting occasional projects, where we do not have the expertise or resource in-house.

A dedicated group of patient ambassadors also supports the work of the organisation. We have a reduced group at the time of writing due to illness and will be looking to recruit further ambassadors.

Hitting the 21-year milestone led to reflections and some adaptations to our 3-year strategy to ensure effectiveness and sustainability. NCUK's Strategic Aims are unchanged:

1. We act as a bridge between hospital and home.
2. We represent the voice of our community.
3. We build a collaborative community of people, knowledge, and expertise.
4. We support people affected by neuroendocrine cancer.
5. We strive to improve the patient pathway.

The following are the key achievements in 2022/23 for each of our Pillars of activity:

Advocacy and campaign work

Successful launch of our Spotlight campaign - a campaign to raise awareness and provide top-line education to HCPs who are not specialist in neuroendocrine cancer but are seeing neuroendocrine cancer patients. As an example, the GP arm of the campaign reached over 45,000 GPs with information about neuroendocrine cancer.

Successful launch of our Advancing Research campaign which exceeded the fundraising target of £50,000 in the first year.

Policy and political work

Successful launch of the 'first of its kind' ideal neuroendocrine cancer pathway for patients with neuroendocrine cancer of the gastrointestinal tract and lung.

Information provision

Delivery of our flagship patient information project in the form of an online, interactive handbook, which acts as a toolkit for anyone diagnosed and living with neuroendocrine cancer.

Educational programmes

Launch of our strategically-planned national education webinar series (N.E.W.S):

- Free events to empower and educate patients about all aspects of neuroendocrine cancer
- Invaluable support, knowledge, and sense of community for those affected
- Talks delivered by expert HCP faculty
- Interactive workshops, panel discussions, clinical lectures
- Talks are filmed and available online
- 1 meeting every 3 months across all UK regions.

Awareness and comms activity

Development of our podcast series – Not Just NE Cancer:

- A podcast covering real life experiences, practical advice & everything in-between
- Interviews with HCPs, organisations & those living with the condition
- Topics from initial diagnosis, treatments and follow up, looking after your mental health and professional perspectives
- Podcast 'take-overs' to focus on specific areas e.g., research.

This podcast was voted number 9 in the 40 best UK cancer podcasts.

Support service work

Running 300 support meetings throughout the budget year, supporting the largest population of patients and family members since our inception and developing our psychotherapy service to include two separate group sessions for those just diagnosed and living with neuroendocrine cancer.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Note from the CEO Cathy Bouvier Ellis

We support all those affected by neuroendocrine cancer through our support and information work, we influence infrastructure and optimal care through our advocacy and policy work, and we address public perceptions of neuroendocrine cancer through our education and awareness work.

We do this because, although we have seen an increased knowledge and understanding with respect to classification, pathogenesis, treatment, and research regarding neuroendocrine cancers, and we have seen the growth of patient advocacy and real-world data about the lived experience of the patient community, we have also witnessed, heard and listened to the significant challenges a newly diagnosed patient has to contend with - a sense of being invisible, surrounded by the unfamiliar, especially terminology, diagnostics and treatments, not conforming to the 'treatment, recovery and survivorship/decline' model of cancer care, coping with uncertainty and ultimately having to live with cancer.

Our key commitments for 2022-2025 are to educate, inform, support and influence 5 key target groups: our community, the public, social/welfare organisations, the clinical community, and policy/political decision makers.

There are 12 key activities laid out below to ensure alignment, optimum impact, and success. Each activity has been grouped under one of our 3 workplans.

External workplan

- a. Continue to grow our community through strong outreach and campaign work - match our perceived impact numbers to our database figures
- b. Develop and encourage collaborative projects around educational initiatives to share resource and funds
- c. Complete, drive and integrate our vital policy work on the neuroendocrine cancer patient pathway and National Access Plan
- d. Optimise our 'shop front' website and patient materials, with a focus on ease of access and accessibility for all.

Internal workplan

- e. Revising current external workplan to prioritise key outputs for the next 3 years based on robust plans, realistic timelines, and adequate budget. This has been adapted to reflect learnings from 2022/2023
- f. Revise and simplify our current campaign work to ensure maximum transparency, readability, focus and impact
- g. Develop deliverable and targeted communications and digital strategies
- h. Revisiting our organisational structure to maximise skills and capability and to understand the organisational resource gaps
- i. Increase and optimise the use of current data and digital technologies for improved reporting and data management
- j. Complete a Trustee review, increase the Trustee board, and review current Trustee policies and procedures. The Trustee review is planned for the November 2023 Trustee meeting and all paperwork delivered to Trustees for completion.

Funding Workplan

- k. Develop a strong financial plan and budget, with key coding references that mirror the activities of the organisation and preparation for any foreseen economic difficulties
- l. Increase and diversify our income streams.

This year has had its challenges, with the amount of work we had planned, the demands foreseen and unforeseen, requests to the organisation for support and the complexity of the disease area we specialise in. This has led to a workforce that is certainly feeling the pressure placed upon it. Third sector organisations across the UK are feeling such pressure and demands, with very little support, and the next year will be planned with this in mind.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £61,439 (2022 £11,244) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £750,214 (2022 £688,775) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies. Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs.

Structure, governance and management

The NET Patient Foundation was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words "incorporating Living with Carcinoid". On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

Mrs R Littlejohn	(Resigned 16 March 2023)
Dr R Srirajaskanthan	
Mrs I Wotherspoon	(Resigned 14 February 2023)
Mr J Kent	
Mr T Jackson	
Mr P Gwilliam (Chairman)	
Mr D Bartlett	(Appointed 21 November 2022)
Ms E Brown	(Appointed 20 January 2023)

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
TRUSTEES' REPORT (CONTINUED)**

FOR THE YEAR ENDED 30 SEPTEMBER 2023

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The Trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All Trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The Trustees report was approved by the Board of Trustees.



.....
Mr P Gwilliam (Chairman)
Trustee

Date: 06/02/2024.....

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK**

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2023.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Anna Chapman FCA
Chapman Worth Limited
2 The Old Estate Yard
High Street
East Hendred
Wantage
Oxfordshire
OX12 8JY

Dated:
6/2/2024

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT**

FOR THE YEAR ENDED 30 SEPTEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Total 2022 £
Income from:					
Donations and legacies	3	472,828	14,195	487,023	348,111
Grants	4	-	2,300	2,300	50,424
Investments	5	2,885	-	2,885	230
Total income		<u>475,713</u>	<u>16,495</u>	<u>492,208</u>	<u>398,765</u>
Expenditure on:					
Raising funds	6	2,637	-	2,637	11,834
Charitable activities	7	369,982	58,149	428,131	375,687
Total resources expended		<u>372,619</u>	<u>58,149</u>	<u>430,768</u>	<u>387,521</u>
Net incoming/(outgoing) resources before transfers		103,094	(41,654)	61,440	11,244
Gross transfers between funds		(3,520)	3,520	-	-
Net income/(expenditure) for the year/ Net movement in funds		<u>99,574</u>	<u>(38,134)</u>	<u>61,440</u>	<u>11,244</u>
Fund balances at 1 October 2022		641,697	47,078	688,775	677,531
Fund balances at 30 September 2023		<u><u>741,271</u></u>	<u><u>8,944</u></u>	<u><u>750,215</u></u>	<u><u>688,775</u></u>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL POSITION**

AS AT 30 SEPTEMBER 2023

	Notes	2023		2022	
		£	£	£	£
Current assets					
Debtors	13	571		16,192	
Cash at bank and in hand		759,909		686,515	
		<u>760,480</u>		<u>702,707</u>	
Creditors: amounts falling due within one year	14	(10,265)		(13,932)	
Net current assets			<u>750,215</u>		<u>688,775</u>
Income funds					
Restricted funds	15		8,944		47,078
Unrestricted funds - general			741,271		641,697
			<u>750,215</u>		<u>688,775</u>

The financial statements were approved by the Trustees on 06/02/2024



.....
Mr P Gwilliam (Chairman)
Trustee

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023**

1 Accounting policies

(Continued)

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023**

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

3 Donations and legacies

	Unrestricted funds general 2023 £	Restricted funds 2023 £	Total 2023 £	Total 2022 £
Donations and gifts	448,030	14,195	462,225	347,391
Legacies receivable	24,798	-	24,798	720
	<u>472,828</u>	<u>14,195</u>	<u>487,023</u>	<u>348,111</u>
For the year ended 30 September 2022	<u>315,826</u>	<u>32,285</u>		<u>348,111</u>

4 Grants

	Society for Endocrine 2023 £	Total 2023 £	Ipsen 2022 £	AAA 2022 £	Total 2022 £
Performance related grants	<u>2,300</u>	<u>2,300</u>	<u>25,424</u>	<u>25,000</u>	<u>50,424</u>

5 Investments

	Unrestricted funds general 2023 £	Total 2022 £
Interest receivable	<u>2,885</u>	<u>230</u>

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

6 Raising funds

	Unrestricted funds general 2023 £	Total 2022 £
<u>Fundraising and publicity</u>		
Other fundraising costs	2,637	11,834
	<u>2,637</u>	<u>11,834</u>

7 Charitable activities

	2023 £	2022 £
Staff costs	153,597	137,452
Strategic Activities	122,741	85,354
Computer costs	11,084	8,521
Advertising and marketing	4,774	1,429
Travel and subsistence	4,417	2,045
Telephone	2,850	3,771
Office expenses	8,187	6,541
Legal and professional	3,800	6,123
Other costs	330	1,960
	<u>311,780</u>	<u>253,196</u>
Grant funding of activities (see note 9)	7,115	26,475
Share of support costs (see note 10)	105,379	91,925
Share of governance costs (see note 10)	3,857	4,091
	<u>428,131</u>	<u>375,687</u>
Analysis by fund		
Unrestricted funds - general	369,982	330,308
Restricted funds	58,149	45,379
	<u>428,131</u>	<u>375,687</u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023**

8 Description of charitable activities

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

9 Grants paid

	2023	2022
NCUK Virtual Toolkit	7,088	3,163
NCRAS Project	-	23,312
NCUK Life Alliance	27	-
	<u>7,115</u>	<u>26,475</u>

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

10 Support costs

	Support costs	Governance costs	2023	Support costs	Governance costs	2022	Basis of allocation
	£	£	£	£	£	£	
Staff costs	86,137	-	86,137	51,569	-	51,569	Administrative staff
Office expenses	1,208	-	1,208	6,325	-	6,325	13% of the cost (2022 32%)
Legal and professional	2,854	-	2,854	3,874	-	3,874	43% of the cost (2022 77%)
Computer costs	1,666	-	1,666	5,328	-	5,328	13% of the cost (2022 39%)
Advertising and marketing	-	-	-	612	-	612	0% of the cost (2022 30%)
Rent and rates	12,643	-	12,643	23,348	-	23,348	100% of the cost (2022 100%)
Telecommunications	186	-	186	419	-	419	6% of the cost (2022 10%)
Other costs	685	-	685	450	-	450	67% of the cost (2022 25%)
Accountancy fees	-	3,857	3,857	-	4,091	4,091	Governance
	<u>105,379</u>	<u>3,857</u>	<u>109,236</u>	<u>91,925</u>	<u>4,091</u>	<u>96,016</u>	
Analysed between							
Charitable activities	<u>105,379</u>	<u>3,857</u>	<u>109,236</u>	<u>91,925</u>	<u>4,091</u>	<u>96,016</u>	

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the independent examiners of £1,986 (2022- £1,872) for independent examination fees.

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

11 Trustees

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year.

12 Employees

The average monthly number of employees during the year was:

	2023	2022
	Number	Number
	9	9
	<u>9</u>	<u>9</u>

Employment costs

	2023	2022
	£	£
Wages and salaries	216,160	172,462
Social security costs	19,094	12,665
Other pension costs	4,480	3,894
	<u>239,734</u>	<u>189,021</u>

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2023	2022
	Number	Number
> £60,000	1	1
£10,000 to £60,000	8	8
	<u>9</u>	<u>9</u>

13 Debtors

	2023	2022
	£	£
Amounts falling due within one year:		
Trade debtors	1	12,500
Other debtors	410	3,692
Prepayments and accrued income	160	-
	<u>571</u>	<u>16,192</u>

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

14 Creditors: amounts falling due within one year

	2023	2022
	£	£
Other taxation and social security	4,629	5,360
Trade creditors	1,007	5,441
Other creditors	2,643	1,259
Accruals and deferred income	1,986	1,872
	<u>10,265</u>	<u>13,932</u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

FOR THE YEAR ENDED 30 SEPTEMBER 2023

15 Restricted funds

The Income Funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at October 2021	Incoming resources	Movement in funds Resources expended	Transfers	Balance at 30 September 2023
	£	£	£	£	£
AAA - Data Extraction / Medical Writing Project	478	-	-	-	478
AAA - NCUK Summit	5,216	-	-	-	5,216
AAA - Patient Travel / Welfare Support	3,675	-	(2,425)	-	1,250
Ipsen - Pathway Project	25,424	300	(25,724)	-	-
Advanced Research	12,285	14,195	(30,000)	3,520	-
Society for Endocrine	-	2,000	-	-	2,000
	<u>47,078</u>	<u>16,495</u>	<u>(58,149)</u>	<u>3,520</u>	<u>8,944</u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023**

16 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total Unrestricted funds 2023 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 30 September 2023 are represented by:					
Current assets/(liabilities)	741,271	8,944	750,215	47,078	688,775
	<u>741,271</u>	<u>8,944</u>	<u>750,215</u>	<u>47,078</u>	<u>688,775</u>

17 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2023 £	2022 £
Aggregate compensation	<u>66,572</u>	<u>65,613</u>

NEUROENDOCRINE CANCER UK

England & Wales - Charity number 1092386

Accounts

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2022**

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr D Jones	(Resigned 25 February 2022)
Mrs M Phillips	(Resigned 12 October 2021)
Mrs R Littlejohn	
Dr R Srirajaskanthan	
Mrs I Wotherspoon	
Mr John Kent	(Appointed 1 December 2021)
Mr Tom Jackson	
Mr P Gwilliam (Chairman)	

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

Supplier payment policy


The company's current policy concerning the payment of trade creditors is to follow the CBI's Prompt Payers Code (copies are available from the CBI, Centre Point, 103 New Oxford Street, London WC1A 1DU).

The company's current policy concerning the payment of trade creditors is to:

- settle the terms of payment with suppliers when agreeing the terms of each transaction;
- ensure that suppliers are made aware of the terms of payment by inclusion of the relevant terms in contracts; and
- pay in accordance with the company's contractual and other legal obligations.

Trade creditors of the company at the year end were equivalent to 5 day's purchases, based on the average daily amount invoiced by suppliers during the year.

The Trustees report was approved by the Board of Trustees.



.....
Mr P Gwilliam (Chairman)
Trustee

Date: 16th March 2023
.....

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2022**

	Notes	2022 £	£	2021 £	£
Current assets					
Debtors	13	16,192		2,866	
Cash at bank and in hand		686,515		678,355	
		<u>702,707</u>		<u>681,221</u>	
Creditors: amounts falling due within one year	14	<u>(13,932)</u>		<u>(3,689)</u>	
Net current assets			<u>688,775</u>		<u>677,532</u>
Income funds					
Restricted funds	15		47,078		17,060
Unrestricted funds - general			641,697		660,472
			<u>688,775</u>		<u>677,532</u>

The financial statements were approved by the Trustees on 16th March 2023



 Mr P Gwilliam (Chairman)
 Trustee

NEUROENDOCRINE CANCER UK

England & Wales - Charity number 1092386

Accounts

Charity Registration No. 1092386

NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	Mr P Gwilliam (Chairman) Mrs R Littlejohn Dr R Srirajaskanthan Mrs I Wotherspoon Mr John Kent Mr Tom Jackson	(Appointed 1 December 2021) (Appointed 7 June 2021)
Charity number	1092386	
Principal address	Second Floor Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 4JL	
Independent examiner	Chapman Worth Limited 3 The Old Estate Yard High Street East Hendred Wantage Oxfordshire OX12 8JY	
Bankers	Lloyds Bank Butler Place Branch PO Box 100 BX1 1LT	

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
CONTENTS**

	Page
Trustees' report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Statement of financial position	7
Notes to the financial statements	8 - 20

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2021

The Trustees have the pleasure in presenting the Trustees' Report and Accounts of Neuroendocrine Cancer UK for the year ended 30 September 2021. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016).

Objectives

The constitutional Objectives of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are, (i) equality of care for all Neuroendocrine Cancer patients in the UK, (ii) excellence in support, care, treatment, and research, (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types, (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

Terminology, Purpose and Need

The umbrella name for Neuroendocrine Cancers was changed by the World Health Organisation in 2017 to neuroendocrine neoplasms (NENs), incorporating tumours and neuroendocrine carcinomas. NENs are a group of unusual and unpredictable tumours which develop from cells in the diffuse endocrine system. NENs can affect people of any age and can be benign (non-cancerous) or malignant (cancerous). Neuroendocrine Cancer UK supports patients with malignant NENs (neuroendocrine cancer) which mostly arise in the lung or gastrointestinal system (but can occur in many organs of the body). Every year about 5,000 people are diagnosed with NENs in the UK with around 40,000 living with the disease. Incidence has increased from 4.6 per 100,000 to 8.7 per 100,000 recorded in 2016.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, sadness, and anxiety. For NEN patients specifically the prospect of a cure is often nil and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis, they can often be treated for the wrong disease meaning their cancer pathway begins with feelings of extreme frustration.

The results of our Barriers to Diagnosis Survey highlighted that more than half of our respondents were referred for further investigations or secondary care review by their GP, 20% presented through A&E and 20% were referred on by hospital doctors they were seeing for another condition. If referred by a hospital doctor - specialist team referral rose to 8%. 52% of respondents receive a diagnosis of Neuroendocrine Cancer following first referral to secondary (or tertiary) care. Of those who did not receive a diagnosis at this time - a third returned to their GP - with 29% visiting a further 1-2 times before being diagnosed, 17% visiting 3-5 times, 7.5% visiting 6-8 times, 5% visiting 8-10 times and 16% visiting more than 10 times before obtaining an accurate diagnosis.

For those who continued through secondary care - 40% had 1-2 visits before receiving a diagnosis of NC, 32% visited 3-5 times, however >28% required more than 6 further visits (12% more than 10).

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

Following a referral, treatment is often the next stage, and this requires patients to address the gravity of their diagnosis at home and often without regular access to the support of doctors and nurses. Therefore, patients frequently suffer from feelings of abandonment and struggle to know who to confide in. Indeed, if their cancer is particularly advanced, they face the possibility of dying. From our experience the complexity of NENs means that patients, family, and friends often struggle to comprehend their suffering. Our Psychotherapy service saw an increase in demand and our budget for this service represented that increase with a doubling of funds. Despite this increase in funds, demand led to a cease in service provision through Nov/Dec to catch up with the backlog.

People with a less common cancer like NENs are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experiences and to take positive and meaningful steps to address them.

Achievements and performance

The CEO is supported by a full-time specialist nurse and a team of administrative and communications staff. A dedicated group of patient ambassadors also support the work of the organization and further ambassadors were added to the team this year totalling 12 to date.

Our services continue to be developed and grown, and key achievements are listed below:

- Launch of the Bridging the Gap Campaign - <https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer-uk-launches-bridging-the-gap-campaign/>
- NCRAS project development improving our understanding around the incidence and prevalence of disease, routes to diagnosis, secondary cancers and health economics surrounding a NEN diagnosis
- Two publications into international journals covering patient perspectives from diagnosis, through treatments and beyond, and the role of patient support groups in NENs.
- Publication of Barriers to Diagnosis survey
- Complete revision of patient factsheets with additional informational resources
- Development of the 'NETInfo' factsheets for the international community
- Presentations at national and international meetings
- Our CEO continuing her work as President of the International Neuroendocrine Cancer Alliance.
- Development of online Natters groups and 167 meetings held in the financial year
- Launch of the NCUK Nurse Academy - <https://ncukacademy.org.uk/>
- Policy work expanded through the NHS charities forum and work with Cancer 52

Note from the CEO Cathy Bouvier

NCUK has been a formal entity since 2001 and so this year marks its 20th anniversary. There have been many changes and adaptations as we have matured and grown, but the ethos of the organisation has remained firm, and the voice of our community is key to our strategic plans. Towards the latter part of this financial year work has started on looking at the next 3-5 years, where we are, where we want to be and what we need to do to get there. We need to ensure that we have the right staff in both quantity and quality, to drive some important and challenging projects forward.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2021

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £214,538 for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £677,532 and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. This level of reserves is in line with the reserves policy of the charity and ensures that it can prepare these accounts on a going concern basis with sufficient contingency if the level of grants and donations should fall during a period of increased economic uncertainty.

Structure, governance and management

The NET Patient Foundation was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words "incorporating Living with Carcinoid". On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The Trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All Trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Trustees who served during the year and up to the date of signature of the financial statements were:


**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
TRUSTEES' REPORT (CONTINUED)**

FOR THE YEAR ENDED 30 SEPTEMBER 2021

Mr P Gwilliam (Chairman)	
Mr D Jones	(Resigned 25 February 2022)
Mrs M Phillips	(Resigned 12 October 2021)
Mrs R Littlejohn	
Dr R Srirajaskanthan	
Mrs I Wotherspoon	
Mr John Kent	(Appointed 1 December 2021)
Mr Tom Jackson	(Appointed 7 June 2021)

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The Trustees report was approved by the Board of Trustees.


.....
Mr P Gwilliam (Chairman)
Trustee
Dated: 26/5/22

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK**

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2021.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Anna Chapman FCA
Chapman Worth Limited
3 The Old Estate Yard
High Street
East Hendred
Wantage
Oxfordshire
OX12 8JY

Dated:

6 July 2022

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Total 2020 £
<u>Income from:</u>					
Donations and legacies	3	541,146	-	541,146	223,684
Grants	4	-	34,410	34,410	71,120
Investments	5	13	-	13	170
Total income		<u>541,159</u>	<u>34,410</u>	<u>575,569</u>	<u>294,974</u>
<u>Expenditure on:</u>					
Raising funds	6	8,021	-	8,021	4,958
Charitable activities	7	252,017	100,993	353,010	282,340
Total resources expended		<u>260,038</u>	<u>100,993</u>	<u>361,031</u>	<u>287,298</u>
Net income/(expenditure) for the year/ Net movement in funds		281,121	(66,583)	214,538	7,676
Fund balances at 1 October 2020		379,351	83,643	462,994	465,411
Fund balances at 30 September 2021		<u><u>660,472</u></u>	<u><u>17,060</u></u>	<u><u>677,532</u></u>	<u><u>473,087</u></u>

The statement of financial activities includes all gains and losses recognised in the year.


All income and expenditure derive from continuing activities.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
STATEMENT OF FINANCIAL POSITION**

AS AT 30 SEPTEMBER 2021

	Notes	2021 £	£	2020 £	£
Current assets					
Debtors	13	2,866		2,461	
Cash at bank and in hand		678,355		476,485	
		<u>681,221</u>		<u>478,946</u>	
Creditors: amounts falling due within one year	14	<u>(3,689)</u>		<u>(5,859)</u>	
Net current assets			<u>677,532</u>		<u>473,087</u>
Income funds					
Restricted funds	16		17,060		83,643
Unrestricted funds - general			660,472		389,444
			<u>677,532</u>		<u>473,087</u>

The financial statements were approved by the Trustees on 26/5/22


.....
Mr P Gwilliam (Chairman)
Trustee

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

The trustees have assessed the implications of the ongoing pandemic on the charity's ability to continue for the foreseeable future and believe that the charity has adequate reserves to meet costs where there is a reduction in income for a significant period in the future. Income for the first quarter of the current year is running at a level that substantiates this assessment.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

FOR THE YEAR ENDED 30 SEPTEMBER 2021

1 Accounting policies

(Continued)

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

3 Donations and legacies

	Unrestricted funds general 2021 £	Total 2020 £
Donations and gifts	437,771	211,324
Legacies receivable	103,375	12,360
	<u>541,146</u>	<u>223,684</u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

4 Grants	Ipsen 2021 £	AAA 2021 £	Lottery 2021 £	Total 2021 £	Ipsen 2020 £	AAA 2020 £	Lottery 2020 £	ITM 2020 £	Total 2020 £
Performance related grants	14,000	16,858	3,552	34,410	9,800	43,827	7,500	9,993	71,120

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

5 Investments

	Unrestricted funds general 2021 £	Total 2020 £
Interest receivable	13	170
	<u>13</u>	<u>170</u>

6 Raising funds

	Unrestricted funds general 2021 £	Total 2020 £
<u>Fundraising and publicity</u>		
Other fundraising costs	8,021	4,958
	<u>8,021</u>	<u>4,958</u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

7 Charitable activities

	2021 £	2020 £
Staff costs	88,802	85,359
Charitable activities	100,548	62,208
Computer costs	2,192	1,973
Advertising and marketing	11,263	7,155
Travel and subsistence	1,777	5,055
Rent	9,127	9,057
Telephone	3,256	3,693
Office expenses	8,579	11,171
Legal and professional	2,438	3,300
Other costs	3,496	2,844
	<u>231,478</u>	<u>191,815</u>
Grant funding of activities (see note 9)	25,600	-
Share of support costs (see note 10)	91,839	84,914
Share of governance costs (see note 10)	4,093	5,611
	<u>353,010</u>	<u>282,340</u>
Analysis by fund		
Unrestricted funds - general	252,017	253,882
Restricted funds	100,993	28,458
	<u>353,010</u>	<u>282,340</u>

8 Description of charitable activities

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

9 Grants payable

	2021	2020
	£	£
Kings College Hospital	25,000	-
Royal College of Nursing	600	-
	<u>25,600</u>	<u>-</u>
	<u><u>25,600</u></u>	<u><u>-</u></u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

10 Support costs	Support Governance costs		2021		Support Governance costs		2020		Basis of allocation	
	£	£	£	£	£	£	£	£		
Staff costs	76,328	-	76,328	69,203	-	69,203	69,203	Administrative staff		
Office expenses	2,145	-	2,145	2,793	-	2,793	2,793	20% of the cost (2020 20%)		
Legal and professional	609	-	609	825	-	825	825	20% of the cost (2020 20%)		
Computer costs	6,576	-	6,576	5,917	-	5,917	5,917	75% of the cost (2020 75%)		
Rent and rates	3,912	-	3,912	3,882	-	3,882	3,882	30% of the cost (2020 30%)		
Telecommunications	1,395	-	1,395	1,583	-	1,583	1,583	30% of the cost (2020 30%)		
Other costs	874	-	874	711	-	711	711	20% of the cost (2020 20%)		
Audit fees	-	4,093	4,093	-	4,228	4,228	4,228	Governance		
Trustees expenses	-	-	-	-	1,383	1,383	1,383	Governance		
	<u>91,839</u>	<u>4,093</u>	<u>95,932</u>	<u>84,914</u>	<u>5,611</u>	<u>90,525</u>	<u>90,525</u>			
Analysed between										
Charitable activities	<u>91,839</u>	<u>4,093</u>	<u>95,932</u>	<u>84,914</u>	<u>5,611</u>	<u>90,525</u>	<u>90,525</u>			

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the Independent Examiner of £1,872 (2020- £1,872) for the Independent Examination.

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

11 Trustees

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year. One of the trustees received a payment of £850 for acting as an NCUK Academy speaker.

During the year Trustees donated a total of £240 (2020 - £240) to general funds.

12 Employees

The average monthly number of employees during the year was:

	2021	2020
	Number	Number
	6	5
	<u>6</u>	<u>5</u>
Employment costs	2021	2020
	£	£
Wages and salaries	149,950	141,337
Social security costs	11,552	9,970
Other pension costs	3,628	3,255
	<u>165,130</u>	<u>154,562</u>

There were no employees whose annual remuneration was more than £60,000.

13 Debtors

	2021	2020
Amounts falling due within one year:	£	£
Other debtors	2,866	2,461
	<u>2,866</u>	<u>2,461</u>

14 Creditors: amounts falling due within one year

	2021	2020
	£	£
Other taxation and social security	834	2,482
Other creditors	983	1,505
Accruals and deferred income	1,872	1,872
	<u>3,689</u>	<u>5,859</u>

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

15 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £3,627 (2020:£3,255).

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

16 Restricted funds

The Income Funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at October 2020	Movement in funds		Balance at 30 September 2021
		Incoming resources	Resources expended	
	£	£	£	£
IEL - App Project	15,181	-	(10,800)	4,381
Ipsen - Publicity/PR	3,335	-	(404)	2,931
AAA - Data Extraction / Medical Writing Project	14,000	-	(11,264)	2,736
AAA - NCUK Summit	8,500	-	(3,284)	5,216
AAA - Nurse Course	9,800	-	(9,800)	-
AAA - Patient Travel / Welfare Support	5,000	-	(3,204)	1,796
AAA - Psychological Support	6,527	-	(6,527)	-
Ipsen -Nurse Course	9,800	-	(9,800)	-
ITM - Mind the Gap Project	4,000	-	(4,000)	-
Lottery - Psychological Support	7,500	-	(7,500)	-
Ipsen - GP Course	-	14,000	(14,000)	-
Ipsen - Patient information Fact Sheets	-	1,776	(1,776)	-
AAA - GP Course	-	15,776	(15,776)	-
AAA - Patient information Fact Sheets	-	1,776	(1,776)	-
AAA - Royal College of Nursing Accreditation	-	1,082	(1,082)	-
	83,643	34,410	(100,993)	17,060

**NEUROENDOCRINE CANCER UK
PREVIOUSLY NET PATIENT FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021**

17 Analysis of net assets between funds

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Total 2020 £
Fund balances at 30 September 2021 are represented by:				
Current assets/(liabilities)	660,472	17,060	677,532	473,087
	<u>660,472</u>	<u>17,060</u>	<u>677,532</u>	<u>473,087</u>

18 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2021 £	2020 £
Aggregate compensation	<u>63,233</u>	<u>59,192</u>